Dassault Systemes and Inserm Announce Joint Agreement to Accelerate Clinical Research Programs

By CIOReview | Wednesday, March 30, 2016
691
1091
211

FREMONT, CA: Dassault Systemes, the 3D EXPERIENCE Company, a player in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, and the French National Institute of Health and Medical Research institution (Inserm),  have announced the signature of a joint agreement to accelerate clinical research programs by deploying a virtual collaborative platform. The agreement will draw from the expertise of each organization to offer new perspectives for addressing scientific and health challenges of the 21st century.

Inserm will utilize Dassault Systemes’ 3DEXPERIENCE platform to conduct its strategic biomedical research programs in the areas of aging, cancer, genomics and microbiota. The platform bestows Inserm with an integrated virtual environment for open collaborative research, unified laboratory management and biological and chemical modeling and simulation from Dassault Systemes’ flagship brand dedicated to scientific excellence, BIOVIA.

In turn, Dassault Systemes will leverage big data from Inserm’s research programs to calibrate and validate scientific models that can be applied to future technologies for the clinical research domain. These models will enable the company to develop next-generation industry solution experiences targeting clinical trials to enable earlier efficacy and safety demonstration with virtual trials.

“We seek out technologies that further our mission to observe and understand mechanisms of the living body and ultimately transfer this knowledge to therapeutic solutions for new and mutating diseases that are affecting the world’s growing population,” said Professor Yves Levy, Chairman and CEO, Inserm. "We lead long-term, competitive scientific programs in human health and medicine and the Dassault Systemes’ 3DEXPERIENCE platform will help us support collaboration, project management, data, resources, traceability and other processes."

“At its core, Dassault Systemes is a scientific company. And at its core, Inserm explores the finest elements of life as we know it—fundamental science. Clinical research has been the catalyst for life-changing discoveries during our lifetime, and introducing capabilities such as modeling and simulation coupled with big data science into translational science, opens up new horizons for investigation,” said Bernard Charles, President and CEO, Dassault Systemes.